Astrazeneca (AZN) Other Operating Expenses (2016 - 2026)

Astrazeneca has reported Other Operating Expenses over the past 16 years, most recently at $189.0 million for Q1 2026.

For Q1 2026, Other Operating Expenses rose 67.26% year-over-year to $189.0 million; the TTM value through Mar 2026 reached $457.0 million, up 53.36%, while the annual FY2025 figure was $381.0 million, 51.19% up from the prior year.
Other Operating Expenses for Q1 2026 was $189.0 million at Astrazeneca, up from $100.0 million in the prior quarter.
Over five years, Other Operating Expenses peaked at $784.0 million in Q2 2023 and troughed at $25.0 million in Q3 2024.
A 5-year average of $157.4 million and a median of $100.0 million in 2024 define the central range for Other Operating Expenses.
Biggest five-year swings in Other Operating Expenses: skyrocketed 542.62% in 2023 and later plummeted 92.35% in 2024.
Year by year, Other Operating Expenses stood at $189.0 million in 2022, then tumbled by 43.39% to $107.0 million in 2023, then decreased by 6.54% to $100.0 million in 2024, then changed by 0.0% to $100.0 million in 2025, then soared by 89.0% to $189.0 million in 2026.
Business Quant data shows Other Operating Expenses for AZN at $189.0 million in Q1 2026, $100.0 million in Q4 2025, and $89.0 million in Q3 2025.

Peer Comparison